Armando Oliver, MD
Ophthalmology · Rio Piedras, PRNPI 1013904440
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,060 of the $250,663 with a category attached, or 91.4%. Mallinckrodt Hospital Products Inc. accounts for 82.1% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $93,790, more than ten times the $3,528 reported in 2019. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $885.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$206K
- AbbVie$42K
- Apellis Pharmaceuticals, Inc.$750
- Bausch & Lomb Americas Inc.$711
- Regeneron Healthcare Solutions, Inc.$486
- Novartis$374
- plus $1K from 13 others
What the payments were for
- Consulting fees$4,5002%
- Speaking & faculty fees$229,06091%
- Travel & lodging$8,6463%
- Food & beverage$8,2913%
- Education$1260%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 106 | $205,727 |
| AbbVie(2 entities) | 90 | $41,571 |
| Apellis Pharmaceuticals, Inc. | 2 | $750 |
| Bausch & Lomb Americas Inc. | 28 | $711 |
| Regeneron Healthcare Solutions, Inc. | 12 | $486 |
| Novartis | 11 | $374 |
| Genentech USA, Inc. | 12 | $227 |
| Alcon Puerto Rico Inc | 4 | $149 |
| Samsara Vision | 1 | $139 |
| Mallinckrodt Enterprises LLC | 1 | $107 |
| ANI Pharmaceuticals, Inc. | 4 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $69 |
| Alcon | 1 | $52 |
| Rhythm Pharmaceuticals, Inc. | 2 | $50 |
| Regeneron | 1 | $49 |
| Genentech, Inc. | 2 | $49 |
| AstraZeneca | 1 | $28 |
| Alimera Sciences, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$204,089
- OZURDEX$36,800
- Syfovre$625
- EYLEA$244
- Implantable Miniature Telescope$139
- enVista MX60 IOL$117
- XIIDRA$101
How this compares
$250,663 in reported general payments places this provider in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 27 | $2,274,853 |
| Humira(Cf) PenAdalimumab | 30 | $210,280 |
| RestasisCyclosporine | 159 | $98,704 |
| Cyclosporine | 113 | $25,251 |
| LumiganBimatoprost | 85 | $22,672 |
| Prednisolone Acetate | 286 | $13,559 |
| Brimonidine Tartrate | 372 | $9,853 |
| Dorzolamide Hcl | 249 | $7,865 |
| Mycophenolate Mofetil | 92 | $7,836 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $7,380 |
| RhopressaNetarsudil Mesylate | 20 | $6,847 |
| AzoptBrinzolamide | 16 | $5,919 |
| VyzultaLatanoprostene Bunod | 19 | $5,643 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 129 | $4,765 |
| Fluorometholone | 73 | $4,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $205,727 | $2,274,85327 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $41,571 | $130,212287 claims |
| AlconAzopt, Simbrinza | $52 | $9,28532 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $711 | $5,64319 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $69 | $2,73817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Rio Piedras
- Carlos Vives AlvaradoRio Piedras$2K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Andres Emanuelli AnzalottaCorozal$50K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
- Antolin Alvarez PontSanturce$10K
- Jaime Bravo CastroSan Juan$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.